Targeting important unmet medical needs

Investor Presentation

Summer 2022

Forward-Looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' (formerly Auris Medical) strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Company Overview

- Nasdaq-listed
- Plans to become an RNA pure play company
- Positioned and plans to be the leading provider of extrahepatic RNA therapeutics – one of the most dynamic emergent sectors in medicine
    - Patented, peptide-based nanoparticles for extrahepatic delivery of RNA as robust technology platform
    - Company's first RNA therapeutic programs target KRAS-driven cancers and rheumatoid arthritis
    - Others R&D initiatives addressing large patient populations are planned
- Active pipeline of non-RNA legacy programs with hundred-million-dollar global TAMs (Bentrio™ & AM-125) advancing in 2022 to key value-added catalysts
    - Plans to spin-off or divest non-RNA legacy assets in 2H-22 following numerous mid-year catalysts
    - …to unlock intrinsic value

Leadership Team

Thomas Meyer | Ph.D.

CEO and Chairman

- Founder Auris Medical (renamed Altamira)
- 14 years with Disetronic Group incl. CEO and BoD
- >20% sales CAGR
- $3B market cap

Samuel Wickline | MD

Chief Scientific Officer

- Prof. of Cardiovascular Sciences, Molecular Physiology and Pharmacology, Medical Engineering at USF

Covadonga Pañeda | Ph.D.

Chief Development Officer

- 18 years experience in FDA/EMA drug development, non-clinical and clinical study design and regulatory submissions,
- incl. 7 years in ophthalmology RNAi at Sylentis

Marcel Gremaud | CPA

Chief Financial Officer

- >30 years' experience in controlling and accounting in international pharma cos and start-ups

Jean Lachance | MBA

Head of OTC Consumer Health Business Unit

- 20 years of experience in sales and marketing in the consumer health & OTC industries in various global, regional, and local roles



Pivoting Towards RNA Therapeutics

Aims to become the leading pure-play company for extrahepatic RNA therapeutics

- Versatile peptide-based delivery platform
  - OligoPhore™ (siRNA Payloads)
  - SemaPhore™ (mRNA Payloads)
- KRAS-driven cancers and rheumatoid arthritis selected as CYTO's first therapeutic indications for OligoPhore™ platform
- Actively exploring additional indications for formal study
- Business plan: license its platform to other biopharmas for additional indications
- Plans to file an IND for KRAS-driven cancers with FDA in 2023

Substantial Market and Growth Opportunities

Great potential in this fast growing and disruptive sector of human medicine



Source: www.researchandmarkets.com; www.alliedmarketresearch.com

Current Challenges with RNA Delivery

- Delivery into target cells and tissues has proved to be a major challenge as RNA is inherently unstable and tends to show poor cellular uptake
- Various delivery technologies have been developed to address these challenges
- Despite substantial progress with delivery of RNA therapeutics to the liver, other target tissues and organs have remained difficult to reach
- Another challenge has been the low amount of RNA payload that becomes available within the cells, which has been reported at 1-2% only
- These challenges have prevented more widespread adoption of RNA therapeutics

Solution: CYTO's Peptide-based Nanoparticles

OligoPhore™ /SemaPhore™ technology enabling safe and effective delivery of RNA payloads with systemic administration. OligoPhore for delivery of siRNA and SemaPhore™ for delivery of mRNA.



Summary of OligoPhore Mechanism of Action

Phore = Greek for agent, bearer
Sema = Greek for sign, message
Oligo = Greek for few, or few similar or identical

- *Stability:* RNA complexed in nanoparticle format for, and only released inside of cells after uptake
- *Extrahepatic delivery:* not sequestered in liver, but permeates inflamed pathological tissues
- *Endosomal escape:* pH-dependent nanoparticle disassembly, followed by full release of RNA into cytoplasm
- *Selectivity:* silences molecular targets in diseased tissues only
- *Safety:* no cellular or adaptive immune responsivity to nanoparticle components or RNA after multiple serial doses, and *no* organ toxicities in mice

RNA Therapeutics Growth Strategy

1. Develop RNA therapeutics to clinical proof of concept for technology platform

- KRAS-driven cancers as first indication for drug development (project AM-401)
  - KRAS mutations present in approximately 25% of tumors, one of the most common gene mutations linked to cancer, driving 32% of lung cancers, 40% of colorectal cancers, and 85% to 90% of pancreatic cancer cases (MD Anderson).
- Aiming for IND in 2023 to be followed by clinical proof-of-concept study
- Rheumatoid arthritis as second indication (project AM-411)
  - Second largest therapeutic area ($56.9bn globally), Humira best selling drug
  - Targeting key inflammation checkpoint with NF-κB (p65) siRNA

2. Leverage technology platform through partnering

- Aim to leverage platform value through collaborations with other biopharmaceutical companies and out-licensing the technology for other indications
- Intend to become a delivery platform company

Mutant KRAS-Driven Tumors

Table 1: Nanoparticle uptake across multiple human and mouse pancreatic and colorectal cancers

Cell line	Cancer species	KRAS status	Mutation	Mutant alleles	% NP uptake
Pancreatic Ductal Adenocarcinoma					
BxPC-3	Human	WT	-	-	96.7
Capan-1	Human	MT	G12V	2	92.3
KCKO	Mouse	MT	G12D	1	83.5
KPC-1	Mouse	MT	G12A	1	99.6
Colorectal Adenocarcinoma					
CT26	Mouse	MT	G12D	2	99.9
MC38	Mouse	WT	-	-	93.8
WUC 322	Human	MT	G12D	1	94.0

NP = nanoparticle, WT = wild type, MT = mutant type.











Strand et al. Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. *Oncotarget*. 2019;10:4761-4775.

Collagen Antibody Induced Arthritis







Reduced inflammation (F), erosions (G), proteoglycan loss (H)

Zhou et al. Peptide-siRNA nanocomplexes targeting NF-kappaB subunit p65 suppress nascent experimental arthritis. *J Clin Invest.* 2014;124:4363-74.

RNA BioPharma Sector Being Revalued: Increasing Capital Flows and Active M&A

- Tidal Therapeutics (mRNA delivery, preclinical stage), acquired in 2021 by Sanofi for $160M upfront + up to $310M milestone payments
- Translate Bio (mRNA delivery), acquired by Sanofi for $3.2B in September 2021
- Dicerna (specializing in RNAi hepatic delivery), acquired by Novo for $3.3B in December 2021



Developments in Non-RNA Legacy Business

Bentrio™ is a novel, drug-free nasal spray

Test-marketed in Germany and Austria in 2H-21. New, growing distribution covers 20+ countries - actively aiming for global.

Protects
as a physical barrier the nasal mucosa

Traps
airborne particles through electrostatic effects

Humidifies
the nasal mucosa and thus aids its functionality

Protects for ≥ 3 hours
Gel designed for extended nasal residence time

Bentrio Clinical Study Developments (in Allergy)

Effective protection demonstrated in allergic rhinitis

Total nasal symptoms during house dust mite challenge



- House dust mite allergen challenge for 3 hours: significant reduction in Total Nasal Symptom Score (TNSS) vs. no treatment (-1.1 points)
- Grass pollen allergen challenge for 4 hours: significant reduction in TNSS (-1.1 points)
- Good safety and tolerability in both studies
- In Australia, NASAR trial ongoing under “real life” conditions with AR patients treating for two weeks vs. saline spray
- Trial data expected 4Q-22 / 1Q-23

Bentrio Study Developments (in Viral Infection)

Positive *in vitro* testing results further confirms broad protection against various types of airborne viruses.

- SARS-CoV-2, including Delta and Omicron variants
  - Significant reduction in viral titer both for prophylaxis (83-99%) and mitigation (69-92%)
- COVAMID trial in acute COVID-19 in Bulgaria and N. Macedonia
  - Target enrolment 180 patients following interim analysis
  - Top-line data expected in early Q4-22
- H1N1 influenza
  - Significant reduction in titer: up to 84% (prophylaxis) and up to 77% (mitigation)
- Human Rhinovirus (HRV)
  - Significant reduction in titer: up to 90% (prophylaxis) and up to 99% (mitigation)

Bentrio Commercialization

- Created OTC Consumer Health business unit to maximize further growth, headed by Big Brand (OTC cough & cold / allergy) industry veteran Jean Lachance who started in May
- Distributor sales ramping up as a function of national clearances / approvals and market launches
- Key collaborations with Nuance Pharma (China) and Wellesta (India, Southeast Asia)
  - $1M upfront received from Nuance, development and commercial milestones up to $22.5M and, upon production transfer, staggered royalty on net sales at high-single to low-double-digit percentage
- FDA 510(k) clearance for treating allergic rhinitis in June 2022
  - More than 20 million US allergic rhinitis sufferers
  - Initial US distribution (online) anticipated later in Q3
  - Company plans to partner US and EU distribution with a major marketer



Advancement in AM-125 Program to Treat Vertigo

AM-125 Potential and Market Plan

Intranasal formulation of betahistine, widely used for decades in tablet form as a vestibular stimulant and standard of care in vertigo treatment & management worldwide – except US.

- Vestibular dysfunction affects more than **one-third** of the U.S. population 40 years of age and older.

- Nasal spray formula circumvents first-pass metabolism
  - AM-125 shows 5-to-29 times higher bioavailability than orally administered betahistine.

- Oral formulation global market size (ex US) = $450M.
  - If approved and marketed in the US and globally, CYTO believes market potential could reach $1 billion or more.

- Intends to pursue distribution partnering opportunities as a more scalable, capital efficient model than in-house distribution and marketing.

AM-125 Clinical Developments

In June, reported positive top-line data from exploratory Phase 2 TRAVERS AM-125 trial





- Demonstrated significant, dose-dependent improvement after four-week treatment with AM-125 nasal spray vs. placebo
  - Faster and more pronounced improvement in balance (Tandem Romberg test)
  - Spontaneous eye movements, a hallmark and objective indicator of vestibular imbalance and vertigo, had fully resolved in 34.5% of the AM-125 20mg group after the treatment period and in 45.2% after six weeks compared with 20% and 25.8%, respectively, in the placebo group
- Good safety and tolerability
- Plan to move the AM-125 program forward by filing IND application with the FDA
- Expects to initiate the next trial later in 2022



Financial Review and Forecast

2021 Financial Highlights

Key Figures

(CHF 1,000, except per-share data)

	FY 2021	FY 2020
Operating Expenses	15,384	5,457
Net Loss	17,390	8,200
Per Share	1.31	1.36
Total Liabilities	6,134	4,029
Shareholder‘s Equity	12,704	16,770

2022 Financings

- In 1Q-22, raised CHF 5 million from FiveT Investment Management Ltd. through a convertible loan agreement
- The loan is convertible into common shares at USD $1.95 per share
- Interest rate of 10% p.a. matures February 8, 2023, if not converted by FiveT or pre-paid by CYTO
- Received USD $1 million as an upfront payment from Nuance Pharma (for Bentrio in Asia)

Cash Requirements for FY 2022

- Expect total cash requirements to be in the range of CHF 11 to 13 million
- Strategic repositioning: deprioritized development programs in tinnitus (Keyzilen®), hearing loss (Sonsuvi®) and antipsychotic induced weight gain (AM-201) and have written off all related intangible assets in 2021
- Can draw upon cash position as well as equity line with Lincoln Park Capital and its “at-the-market” program with A.G.P.
- Other sources of funding may arise from planned spin-off or divestiture of all or parts of non-RNA legacy business in 2H-22



Clinical Development and Regulatory Recap

2022 Catalysts

- Top-line data read-out for the COVAMID trial is expected in early Q4-22
- Plan to advance the AM-125 program forward by filing IND application with the FDA; expect to initiate its next trial later in 2022
- Seasonal allergic rhinitis NASAR clinical trial is expected to report top line data in Q4-22 / Q1-23
- Recent US FDA 510(k) clearance major milestone
- Divesting / spinning-off legacy business key priority for H2 2022
- Transforming into pure play RNA therapeutics business
  - Submit an IND to FDA in 2023 for KRAS-driven cancer treatment
  - Rheumatoid arthritis as second “showcase” development project
  - Pursuing OligoPhore and SemaPhore out-licensing strategy

Contact

investors@altamiratherapeutics.com

www.altamiratherapeutics.com